Highlight of 2023: Virtues and vices of CD4 CAR T cells.

Chinni, Shivali Savita; Taylor, Megan F; Borger, Jessica G; Quinn, Kylie M

Chinni, Shivali Savita; Taylor, Megan F; Borger, Jessica G; Quinn, Kylie M.

Afiliação

Chinni SS; School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Taylor MF; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Borger JG; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.
Quinn KM; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.

Immunol Cell Biol ; 102(6): 432-436, 2024 Jul.

Article em En | MEDLINE | ID: mdl-38659345

ABSTRACT

ABSTRACT

This article for the Highlights of 2023 Series explores recent work that suggests that targeting CD4 CAR T cells may be critical for both of these challenges.

Assuntos

Linfócitos T CD4-Positivos; Imunoterapia Adotiva; Receptores de Antígenos Quiméricos; Humanos; Linfócitos T CD4-Positivos/imunologia; Imunoterapia Adotiva/métodos; Receptores de Antígenos Quiméricos/imunologia; Receptores de Antígenos Quiméricos/metabolismo; Receptores de Antígenos Quiméricos/genética; Animais; Receptores de Antígenos de Linfócitos T/metabolismo; Receptores de Antígenos de Linfócitos T/imunologia

Palavras-chave

CAR T cell therapy; CD4; IFNÎ³; cytokine release syndrome

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD4-Positivos / Imunoterapia Adotiva / Receptores de Antígenos Quiméricos Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google